research

Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting

PITTSBURGH, Oct. 24, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors: Role in Health and Disease. The Symposium will be held in San Diego, California on November 3, 2018 beginning …

Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting Read More »

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum

Pittsburgh, Jan. 04, 2018 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make two presentations at the upcoming Sachs Associates Neuroscience Innovation Forum on January 7, 2018 …

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum Read More »

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Pittsburgh, March 14, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the company’s co-founder and chief science officer, Dr. Susan Catalano, is presenting Phase 1b/2a results demonstrating the unique synaptoprotective mechanism of action …

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting Read More »

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting

Pittsburgh, March 6, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make an oral presentation at the annual meeting of the American Society of …

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting Read More »

Scroll to Top